Karyopharm Therapeutics Inc (KPTI) Receives $17.88 Consensus PT from Brokerages

Karyopharm Therapeutics Inc (NASDAQ:KPTI) has received a consensus recommendation of “Hold” from the thirteen research firms that are currently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $17.88.

Several analysts have recently issued reports on the stock. Wedbush reduced their target price on shares of Karyopharm Therapeutics from $19.00 to $14.00 and set an “outperform” rating for the company in a research note on Monday, February 25th. Zacks Investment Research upgraded shares of Karyopharm Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a research note on Thursday, January 10th. BidaskClub lowered shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 16th. ValuEngine upgraded shares of Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, April 1st. Finally, JPMorgan Chase & Co. lowered shares of Karyopharm Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $21.00 to $7.00 in a research report on Friday, March 1st.

NASDAQ KPTI opened at $4.63 on Tuesday. Karyopharm Therapeutics has a 1 year low of $3.92 and a 1 year high of $21.71. The company has a debt-to-equity ratio of 0.56, a current ratio of 7.13 and a quick ratio of 7.13. The firm has a market capitalization of $293.35 million, a PE ratio of -1.47 and a beta of 3.24.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Thursday, February 28th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.87) by ($0.09). Karyopharm Therapeutics had a negative return on equity of 107.60% and a negative net margin of 588.10%. Analysts forecast that Karyopharm Therapeutics will post -3.64 earnings per share for the current fiscal year.

In related news, major shareholder Ltd Chione sold 1,481,643 shares of the stock in a transaction dated Wednesday, February 27th. The shares were sold at an average price of $4.81, for a total transaction of $7,126,702.83. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 13.26% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. lifted its holdings in Karyopharm Therapeutics by 5.1% during the third quarter. BlackRock Inc. now owns 4,260,531 shares of the company’s stock valued at $72,556,000 after purchasing an additional 204,897 shares during the last quarter. Ridgeback Capital Investments L.P. purchased a new stake in Karyopharm Therapeutics during the fourth quarter valued at about $36,967,000. FMR LLC lifted its holdings in Karyopharm Therapeutics by 51.5% during the fourth quarter. FMR LLC now owns 1,875,140 shares of the company’s stock valued at $17,570,000 after purchasing an additional 637,357 shares during the last quarter. Candriam Luxembourg S.C.A. lifted its holdings in Karyopharm Therapeutics by 65.1% during the fourth quarter. Candriam Luxembourg S.C.A. now owns 1,792,544 shares of the company’s stock valued at $16,795,000 after purchasing an additional 707,044 shares during the last quarter. Finally, Emerald Advisers LLC lifted its holdings in Karyopharm Therapeutics by 109.8% during the fourth quarter. Emerald Advisers LLC now owns 1,456,473 shares of the company’s stock valued at $13,647,000 after purchasing an additional 762,405 shares during the last quarter. Institutional investors own 84.48% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase IIb clinical study in treatments of refractory multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for multiple myeloma patients; Phase III clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; Phase IIb clinical study in diffuse large B-cell lymphoma; Phase II/III clinical study in liposarcoma; Phase III clinical trial in endometrial cancer; and Phase II clinical trial in glioblastoma multiforme.

See Also: Understanding the different types of bonds

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.